No that is not the case. The issue is the additional costs for GHDX in securing required approvals. The product continues to be used and marketed and the market for it continues to grow. Whether that will increase substantially once the registration as a medical device issue is resolved remains to be seen. Today's price action is typical, this stock moves a great deal, on occasion, on relatively little news.